# P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

> **NCT04249947** · PHASE1 · TERMINATED · sponsor: **Poseida Therapeutics, Inc.** · enrollment: 40 (actual)

## Conditions studied

- Prostatic Neoplasms, Castration-Resistant
- Neoplasms by Histologic Type
- Neoplasms, Prostate
- Prostate Cancer
- Metastatic Castration-resistant Prostate Cancer
- Neoplasms
- Prostatic Neoplasms
- Genital Neoplasms, Male
- Urogenital Neoplasms
- Neoplasms by Site
- Prostatic Disease
- Salivary Gland Cancer
- Salivary Gland Tumor
- Adenoid Cystic Carcinoma
- Salivary Duct Carcinoma
- Mucoepidermoid Carcinoma
- Acinic Cell Tumor

## Interventions

- **BIOLOGICAL:** P-PSMA-101 CAR-T cells
- **DRUG:** Rimiducid

## Key facts

- **NCT ID:** NCT04249947
- **Lead sponsor:** Poseida Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-02-28
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Study closed
- **Last updated:** 2025-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04249947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04249947, "P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04249947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*